Melanoma, Skin cancer
Results
Phase 2
This trial looked at docetaxel with or without selumetinib (AZD6244) for people whose melanoma cells didn’t have a change () in a gene called BRAF. This trial was for people whose melanoma had spread to the surrounding or to another part of the body. This is called advanced melanoma.
Doctors sometimes use chemotherapy drugs such as docetaxel (Taxotere) to treat advanced melanoma. But it doesn’t always work very well. Doctors hoped that using a new treatment called selumetinib with docetaxel may have worked better than docetaxel alone.
Selumetinib is a type of drug called a MEK inhibitor and it works by blocking growth signals. MEK is a protein that sends signals to cells telling them to divide and grow. Researchers hoped that selumetinib would reduce the amount of MEK and slow down or stop the growth of cancer.
The aims of this trial were to find out
If docetaxel and selumetinib was better than docetaxel alone for advanced melanoma with no BRAF gene change
More about the side effects
Recruitment start: 26 October 2010
Recruitment end: 21 May 2012
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Mark Middleton
AstraZeneca
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
NIHR Oxford Biomedical Research Centre
University of Oxford
This is Cancer Research UK trial number CRUKE/10/026.
Last reviewed: 11 September 2016
CRUK internal database number: 6195